Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP30 | Q70CQ3 | 3/20 | 0.48 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.44 |
| ▸ | HTR6 | P50406 | 2/20 | 0.44 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.44 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.44 |
| ▸ | CASR | P41180 | 1/20 | 0.43 |
| ▸ | BRD4 | O60885 | 1/20 | 0.42 |
| ▸ | PARP1 | P09874 | 1/20 | 0.42 |
| ▸ | HPGDS | O60760 | 1/20 | 0.41 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.41 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.41 |
| ▸ | KDM1A | O60341 | 1/20 | 0.41 |
| ▸ | BCHE | P06276 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1249864 | 1.00 | USP30 (0.48) | USP30ACKR3HTR6PRMT5WDR77 | |
| SCHEMBL1249860 | 1.00 | USP30 (0.48) | USP30ACKR3HTR6PRMT5WDR77 | |
| SCHEMBL1249503 | 0.87 | EED (0.50) | USP30GPR119 | |
| SCHEMBL1249505 | 0.87 | EED (0.50) | USP30GPR119 | |
| SCHEMBL27830896 | 0.83 | CASR (0.47) | CASRMEN1KMT2A | |
| SCHEMBL27830895 | 0.83 | CASR (0.47) | CASRMEN1KMT2A | |
| SCHEMBL27830892 | 0.83 | CASR (0.47) | CASRMEN1KMT2A | |
| SCHEMBL3611067 | 0.83 | GPR119 (0.49) | USP30ACKR3PRMT5WDR77PARP1 | |
| SCHEMBL3611065 | 0.83 | GPR119 (0.49) | USP30ACKR3PRMT5WDR77PARP1 | |
| SCHEMBL3611070 | 0.83 | GPR119 (0.49) | USP30ACKR3PRMT5WDR77PARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2283000-B1 | 3- OR 4-SUBSTITUTED PIPERIDINE COMPOUNDS | SK BIOPHARMACEUTICALS CO LTD (KR) | 2015-09-23 | — | — | EP | disclosed |
| US-8546576-B2 | 3 or 4-substituted piperidine compounds | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2013-10-01 | — | — | US | disclosed |
| US-8513285-B2 | 3 or 4-substituted piperidine compounds | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2013-08-20 | — | — | US | disclosed |
| US-20120122927-A1 | 3 OR 4-SUBSTITUTED PIPERIDINE COMPOUNDS | LEE KI-HO (KR) | 2012-05-17 | — | — | US | disclosed |
| EP-2283000-A2 | 3- OR 4-SUBSTITUTED PIPERIDINE COMPOUNDS | SK Holdings Co., Ltd. (KR) | 2011-02-16 | — | — | EP | disclosed |
| US-20090306140-A1 | 3 or 4-Substituted Piperidine Compounds | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2009-12-10 | — | — | US | disclosed |
| WO-2009148291-A2 | 3- OR 4-SUBSTITUTED PIPERIDINE COMPOUNDS | SK HOLDINGS CO., LTD. (KR) | 2009-12-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120122927-A1 | 3 OR 4-SUBSTITUTED PIPERIDINE COMPOUNDS | OPRD1, OPRK1, OPRM1 | USP30 4400/4885ACKR3 1190/4885HTR6 26/4885 |
| US-20090306140-A1 | 3 or 4-Substituted Piperidine Compounds | OPRD1, OPRK1, OPRM1 | USP30 4390/4885ACKR3 1125/4885HTR6 22/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.